Effects of Egg Ingestion on Endothelial Function in Adults With Coronary Artery Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01672567 |
Recruitment Status :
Completed
First Posted : August 27, 2012
Last Update Posted : March 26, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease | Dietary Supplement: Egg supplementation Dietary Supplement: Egg substitute Dietary Supplement: Control diet | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 34 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Prevention |
Official Title: | Effects of Egg Ingestion on Endothelial Function in Adults With Coronary Artery Disease: A Randomized, Controlled, Crossover Trial |
Study Start Date : | October 2010 |
Actual Primary Completion Date : | April 2012 |
Actual Study Completion Date : | April 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Egg supplementation
Daily consumption of 2 eggs for breakfast for 6 weeks
|
Dietary Supplement: Egg supplementation
Daily consumption of 2 eggs for breakfast for 6 weeks |
Experimental: Egg substitute
Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
|
Dietary Supplement: Egg substitute
Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks |
Experimental: Control diet
Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
|
Dietary Supplement: Control diet
Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk |
- Endothelial Function Flow mediated dilatation (FMD) as the percent change in brachial artery diameter from pre-cuff inflation to 60 seconds post-cuff release. [ Time Frame: 6 weeks ]FMD will be measured as the percent change in brachial artery diameter from pre-cuff inflation to 60-seconds post-cuff release (upper arm cuff position). In addition to brachial diameter at 60 seconds post-cuff release, flow after cuff deflation within the first 15 seconds will be used as an indicator of stimulus strength, hyperemic flow being the stimulus for endothelial reactivity.
- Fasting Lipid Panel - Total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride level, cholesterol / high density lipoprotein cholesterol ratio [ Time Frame: 6 weeks ]Total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride level, cholesterol / high density lipoprotein cholesterol ratio
- 3-Day Food Diary [ Time Frame: 6 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 35 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males age greater than 35 years;
- Post-menopausal females not currently on hormone replacement therapy;
- Non-smokers;
- CVD as defined by the presence of at least one coronary stenosis >50% determined angiographically or a documented history of myocardial infarction.
Exclusion Criteria:
- Failure to meet inclusion criteria;
- Anticipated inability to complete study protocol for any reason;
- Current eating disorder;
- Use of lipid-lowering or antihypertensive medications unless stable on medication for at least 3 months and willing to refrain from taking medication for 12 hours prior to EF scanning;
- Regular use of high doses of vitamin E or C;
- Use of insulin, glucose-sensitizing medication, vasoactive medication (including glucocorticoids, antineoplastic agents, psychoactive agents, or bronchodilators) or nutraceuticals;
- Regular use of fiber supplements;
- Diabetes;
- Sleep apnea;
- Restricted diets by choice (i.e., vegetarian, vegan);
- Coagulopathy, known bleeding diathesis, or history of clinically significant hemorrhage; current use of warfarin.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01672567
United States, Connecticut | |
Griffin Hospital | |
Derby, Connecticut, United States, 06418 |
Principal Investigator: | David L. Katz, MD, MPH | Yale-Griffin Prevention Research Center |
Responsible Party: | Griffin Hospital |
ClinicalTrials.gov Identifier: | NCT01672567 |
Other Study ID Numbers: |
2010-05 |
First Posted: | August 27, 2012 Key Record Dates |
Last Update Posted: | March 26, 2020 |
Last Verified: | March 2020 |
Coronary Artery Disease Egg Consumption Endothelial Function |
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |